News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amgen (AMGN) Completes Acquisition of Alantos


7/17/2007 11:40:41 AM

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos’s DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes as well as its matrix metalloproteinases platform for osteoarthritis. The acquisition was originally announced June 6.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES